昭衍新药
(603127)
| 流通市值：239.22亿 | | | 总市值：284.38亿 |
| 流通股本：6.30亿 | | | 总股本：7.49亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 316,135,036.49 | 1,657,624,302.72 | 984,961,529.76 | 668,575,211.14 |
| 营业收入 | 316,135,036.49 | 1,657,624,302.72 | 984,961,529.76 | 668,575,211.14 |
| 二、营业总成本 | 334,230,289.38 | 1,663,214,563.55 | 1,025,427,901.11 | 667,394,336.77 |
| 营业成本 | 251,371,799.79 | 1,314,312,169.51 | 772,681,388.3 | 507,935,259.42 |
| 税金及附加 | 3,174,052.51 | 9,102,383.87 | 6,178,941.53 | 4,317,229.34 |
| 销售费用 | 6,152,098.01 | 36,911,659.9 | 22,041,852.96 | 14,608,733.68 |
| 管理费用 | 66,884,931.44 | 282,261,376.13 | 213,574,864.2 | 134,505,155.96 |
| 研发费用 | 19,463,677.91 | 87,428,942.37 | 63,864,270.44 | 43,446,069.62 |
| 财务费用 | -12,816,270.28 | -66,801,968.23 | -52,913,416.32 | -37,418,111.25 |
| 其中:利息费用 | 273,931.51 | 1,421,665.35 | 1,079,303.33 | 776,460.21 |
| 其中:利息收入 | 19,763,775.49 | 78,186,727.67 | 59,549,247.23 | 41,322,974.41 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 283,025,818.05 | 447,560,334.54 | 169,197,862.53 | 107,019,073.28 |
| 加:投资收益 | 4,570,742.76 | 18,013,906.02 | 20,033,342.3 | 13,135,262.03 |
| 资产处置收益 | -20.32 | 413,517.67 | -15,902.95 | -44,025.87 |
| 资产减值损失(新) | -13,705,381.87 | -156,760,636.98 | -76,295,444.28 | -66,010,456.08 |
| 信用减值损失(新) | -2,704,427.75 | 4,086,291.11 | 2,285,614.08 | 5,391,403.55 |
| 其他收益 | 2,827,960.3 | 30,267,966.34 | 24,712,928.01 | 19,183,378.08 |
| 四、营业利润 | 255,919,438.28 | 337,991,117.87 | 99,452,028.34 | 79,855,509.36 |
| 加:营业外收入 | 248,474.79 | 405,289.63 | 387,234.69 | 319,690.6 |
| 减:营业外支出 | 112,521.39 | 903,142.53 | 213,878.21 | 55,626.21 |
| 五、利润总额 | 256,055,391.68 | 337,493,264.97 | 99,625,384.82 | 80,119,573.75 |
| 减:所得税费用 | 17,703,970.15 | 39,650,738.67 | 18,919,337.5 | 19,187,197.37 |
| 六、净利润 | 238,351,421.53 | 297,842,526.3 | 80,706,047.32 | 60,932,376.38 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 238,351,421.53 | 297,842,526.3 | 80,706,047.32 | 60,932,376.38 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 238,356,654.58 | 297,841,047.52 | 80,706,068 | 60,932,399.37 |
| 少数股东损益 | -5,233.05 | 1,478.78 | -20.68 | -22.99 |
| 扣除非经常损益后的净利润 | 217,391,315.27 | 311,475,492.83 | 29,044,730.55 | 23,052,174.74 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.32 | 0.4 | 0.11 | 0.08 |
| (二)稀释每股收益 | 0.32 | 0.4 | 0.11 | 0.08 |
| 八、其他综合收益 | -6,579,713.78 | -19,287,775 | -6,480,220.42 | -2,334,068.82 |
| 归属于母公司股东的其他综合收益 | -6,579,713.78 | -19,287,775 | -6,480,220.42 | -2,334,068.82 |
| 九、综合收益总额 | 231,771,707.75 | 278,554,751.3 | 74,225,826.9 | 58,598,307.56 |
| 归属于母公司股东的综合收益总额 | 231,776,940.8 | 278,553,272.52 | 74,225,847.58 | 58,598,330.55 |
| 归属于少数股东的综合收益总额 | -5,233.05 | 1,478.78 | -20.68 | -22.99 |
| 公告日期 | 2026-04-30 | 2026-03-31 | 2025-10-31 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |